Secondary analysis (virology substudy, 622 analysed) of an open-label RCT in at-risk adults with early COVID-19: nirmatrelvir-ritonavir vs usual care shortened viral half-life (0.66 vs 0.78 days) and cut culturable virus, with no rise in rebound.
Secondary analysisn = 622
Lowe et al. Nirmatrelvir-ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022-23: virological and immunological results of an open-label randomised trial (PANORAMIC)